New study monitors Eplontersen's effects during pregnancy and nursing
NCT ID NCT07205666
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows up to 10 pregnant or breastfeeding individuals with transthyretin amyloidosis who have taken eplontersen, along with their infants. Researchers will track pregnancy complications, birth defects, and infant health during the first year of life. The goal is to describe safety outcomes, not to test the drug's effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eplontersen
- What this could lead to
- If successful, this study could provide important safety information for using eplontersen during pregnancy and breastfeeding.
- What could go wrong
- This is a very small study (10 participants) that only describes outcomes, not tests effectiveness. It may not detect rare risks or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGFrankfurt, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis
- New study tracks safety of eplontersen in patients with liver transplants
- Carpal tunnel surgery could spot hidden heart disease risk
- AI spots heart clues in bone scans: a new way to catch a silent killer?
- Can MRI and nerve tests catch a rare disease before symptoms start?
- New italian registry aims to unlock secrets of rare heart disease